Characterization of CD 26+CD110+ (liver) and CD26+CDCP1+ (lung) cancer stem cell populations, determination of their mutational heterogeneity and the differences of the liver vs. lung niche

CD 26 CD110（肝脏）和 CD26 CDCP1（肺癌）癌症干细胞群的表征、确定其突变异质性以及肝脏与肺生态位的差异

• 批准号: 397674952
• 负责人: Dr. Katharina Jöchle
• 金额: --
• 依托单位: Klinik für Allgemein- und Viszeralchirurgie
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2018
• 资助国家: 德国
• 起止时间: 2017-12-31 至 2018-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/397674952?language=en
• 关键词: Characterization; CD; 26+CD110+; liver; CD26+CDCP1+

Colorectal cancer is the second most frequent cancer in men and women. At time of diagnosis 25% of patients do have metastatic disease and 50% of patients will develop metastases during the course of their disease. This high metastatic rate leads to the majority of patients initially not being candidates for curative resection (1). Further, organspecific metastases do directly impact on overall survival in these patients. Liver metastasis is one of the most important prognosticators. Their resection can significantly improve their survival. Adding to this, recent data has shown a survival benefit for patients in whom all liver metastases are resected in the presence of unresectable lung metastases (2). However, patients with colorectal liver metastases do have a considerably worse prognosis compared to patients with colorectal lung metastases alone (3). Therefore, this suggests that there are differences in tumor biology of colorectal liver and lung metastases. An important subpopulation of cells in colorectal cancer are cancer stem cells (CSC) metastasis that confer the biological behavior and aggressiveness of the colorectal cancer. Cancer stem cells can be detected by their epitopes and thus also be identified in case of metastasis. Today, no further analysis of cancer stem cells concerning organspecific metastasis has been performed and consequently the reason for the differences in aggressiveness of colorectal liver and lung metastases remains unclear. The aim of this project is the characterization of CD 26+CD110+ (liver) and CD26+CDCP1+ (lung) cancer stem cell populations, determination of their mutational heterogeneity and the differences of the liver vs. lung niche.

结直肠癌是男性和女性中第二常见的癌症。 在诊断时，25% 的患者确实患有转移性疾病，50% 的患者在病程中会出现转移。这种高转移率导致大多数患者最初不适合进行根治性切除 (1)。此外，器官特异性转移确实直接影响这些患者的总生存期。肝转移是最重要的预后因素之一。切除它们可以显着提高它们的生存率。除此之外，最近的数据显示，在存在不可切除的肺转移的情况下，所有肝转移都被切除的患者具有生存获益 (2)。然而，与单纯结直肠肺转移的患者相比，结直肠肝转移患者的预后确实要差得多 (3)。因此，这表明结直肠肝转移和肺转移的肿瘤生物学存在差异。结直肠癌中一个重要的细胞亚群是癌症干细胞（CSC）转移，它赋予结直肠癌的生物学行为和侵袭性。癌症干细胞可以通过其表位来检测，因此在发生转移时也可以被识别。目前，尚未对涉及器官特异性转移的癌症干细胞进行进一步分析，因此结直肠肝转移和肺转移侵袭性差异的原因仍不清楚。该项目的目的是表征 CD 26+CD110+（肝脏）和 CD26+CDCP1+（肺癌）癌症干细胞群，确定它们的突变异质性以及肝脏与肺生态位的差异。